A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Identifieur interne : 003234 ( Main/Curation ); précédent : 003233; suivant : 003235A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Auteurs : Maria E. Cabanillas [États-Unis] ; Martin Schlumberger [France] ; Barbara Jarzab [Pologne] ; Renato G. Martins [États-Unis] ; Furio Pacini [Italie] ; Bruce Robinson [Australie] ; Judith C. Mccaffrey [États-Unis] ; Manisha H. Shah [États-Unis] ; Donald L. Bodenner [États-Unis] ; Duncan Topliss [Australie] ; Corina Andresen [États-Unis] ; James P. O'Brien [États-Unis] ; Min Ren [États-Unis] ; Yasuhiro Funahashi [États-Unis] ; Roger Allison [Australie] ; Rossella Elisei [Italie] ; Kate Newbold [Royaume-Uni] ; Lisa F. Licitra [Italie] ; Steven I. Sherman [États-Unis] ; Douglas W. Ball [États-Unis]Source :
- Cancer [ 1097-0142 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques (usage thérapeutique), Femelle, Humains, Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (usage thérapeutique), Marqueurs biologiques tumoraux (analyse), Mâle, Phénylurées (effets indésirables), Phénylurées (usage thérapeutique), Quinoléines (effets indésirables), Quinoléines (usage thérapeutique), Radio-isotopes de l'iode (effets indésirables), Radio-isotopes de l'iode (usage thérapeutique), Résultat thérapeutique, Sujet âgé, Tumeurs de la thyroïde (mortalité), Tumeurs de la thyroïde (traitement médicamenteux), Évolution de la maladie.
- MESH :
- analyse : Marqueurs biologiques tumoraux.
- effets indésirables : Inhibiteurs de protéines kinases, Phénylurées, Quinoléines, Radio-isotopes de l'iode.
- mortalité : Tumeurs de la thyroïde.
- traitement médicamenteux : Tumeurs de la thyroïde.
- usage thérapeutique : Antinéoplasiques, Inhibiteurs de protéines kinases, Phénylurées, Quinoléines, Radio-isotopes de l'iode.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mâle, Résultat thérapeutique, Sujet âgé, Évolution de la maladie.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Agents (therapeutic use), Biomarkers, Tumor (analysis), Disease Progression, Female, Humans, Iodine Radioisotopes (adverse effects), Iodine Radioisotopes (therapeutic use), Male, Middle Aged, Phenylurea Compounds (adverse effects), Phenylurea Compounds (therapeutic use), Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Quinolines (adverse effects), Quinolines (therapeutic use), Thyroid Neoplasms (drug therapy), Thyroid Neoplasms (mortality), Treatment Outcome.
- MESH :
- chemical , adverse effects : Iodine Radioisotopes, Phenylurea Compounds, Protein Kinase Inhibitors, Quinolines.
- chemical , analysis : Biomarkers, Tumor.
- chemical , therapeutic use : Antineoplastic Agents, Iodine Radioisotopes, Phenylurea Compounds, Protein Kinase Inhibitors, Quinolines.
- drug therapy : Thyroid Neoplasms.
- mortality : Thyroid Neoplasms.
- Adult, Aged, Disease Progression, Female, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 through 3 (VEGFR1-VEGFR3), fibroblast growth factor receptors 1 through 4 (FGFR1-FGFR4), platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks implicated in tumor angiogenesis. Positive phase 1 results in solid tumors prompted a phase 2 trial in patients with advanced, radioiodine-refractory, differentiated thyroid cancer (RR-DTC).
DOI: 10.1002/cncr.29395
PubMed: 25913680
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A75
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002A05
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002A05
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002503
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002503
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002503
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003235
Links to Exploration step
pubmed:25913680Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.</title><author><name sortKey="Cabanillas, Maria E" sort="Cabanillas, Maria E" uniqKey="Cabanillas M" first="Maria E" last="Cabanillas">Maria E. Cabanillas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Schlumberger, Martin" sort="Schlumberger, Martin" uniqKey="Schlumberger M" first="Martin" last="Schlumberger">Martin Schlumberger</name><affiliation wicri:level="4"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute and Université Paris-Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute and Université Paris-Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice Poland, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice Poland, Wybrzeze Armii Krajowej 15, 44-101 Gliwice</wicri:regionArea><wicri:noRegion>44-101 Gliwice</wicri:noRegion></affiliation></author><author><name sortKey="Martins, Renato G" sort="Martins, Renato G" uniqKey="Martins R" first="Renato G" last="Martins">Renato G. Martins</name><affiliation wicri:level="2"><nlm:affiliation>Department of Thoracic/Head and Neck Oncology, School of Medicine, University of Washington, Seattle, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>Department of Thoracic/Head and Neck Oncology, School of Medicine, University of Washington, Seattle</wicri:cityArea></affiliation></author><author><name sortKey="Pacini, Furio" sort="Pacini, Furio" uniqKey="Pacini F" first="Furio" last="Pacini">Furio Pacini</name><affiliation wicri:level="1"><nlm:affiliation>Section of Endocrinology, University of Siena, Siena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Section of Endocrinology, University of Siena, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name><affiliation wicri:level="4"><nlm:affiliation>Faculty of Medicine, Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, University of Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Faculty of Medicine, Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, University of Sydney, New South Wales</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Mccaffrey, Judith C" sort="Mccaffrey, Judith C" uniqKey="Mccaffrey J" first="Judith C" last="Mccaffrey">Judith C. Mccaffrey</name><affiliation wicri:level="2"><nlm:affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>H. Lee Moffitt Cancer Center and Research Institute, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Shah, Manisha H" sort="Shah, Manisha H" uniqKey="Shah M" first="Manisha H" last="Shah">Manisha H. Shah</name><affiliation wicri:level="2"><nlm:affiliation>Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Ohio State University Comprehensive Cancer Center, Columbus</wicri:cityArea></affiliation></author><author><name sortKey="Bodenner, Donald L" sort="Bodenner, Donald L" uniqKey="Bodenner D" first="Donald L" last="Bodenner">Donald L. Bodenner</name><affiliation wicri:level="2"><nlm:affiliation>Department of Geriatrics, University of Arkansas for Medical sciences, Little Rock, Arkansas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Arkansas</region></placeName><wicri:cityArea>Department of Geriatrics, University of Arkansas for Medical sciences, Little Rock</wicri:cityArea></affiliation></author><author><name sortKey="Topliss, Duncan" sort="Topliss, Duncan" uniqKey="Topliss D" first="Duncan" last="Topliss">Duncan Topliss</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Andresen, Corina" sort="Andresen, Corina" uniqKey="Andresen C" first="Corina" last="Andresen">Corina Andresen</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="O Brien, James P" sort="O Brien, James P" uniqKey="O Brien J" first="James P" last="O'Brien">James P. O'Brien</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Ren, Min" sort="Ren, Min" uniqKey="Ren M" first="Min" last="Ren">Min Ren</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Funahashi, Yasuhiro" sort="Funahashi, Yasuhiro" uniqKey="Funahashi Y" first="Yasuhiro" last="Funahashi">Yasuhiro Funahashi</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Andover, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Eisai Inc, Andover</wicri:cityArea></affiliation></author><author><name sortKey="Allison, Roger" sort="Allison, Roger" uniqKey="Allison R" first="Roger" last="Allison">Roger Allison</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author><author><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name><affiliation wicri:level="4"><nlm:affiliation>Department of Endocrinology, University of Pisa, Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Endocrinology, University of Pisa, Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region><settlement type="city">Pise</settlement></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Newbold, Kate" sort="Newbold, Kate" uniqKey="Newbold K" first="Kate" last="Newbold">Kate Newbold</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Royal Marsden Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Oncology, Royal Marsden Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Licitra, Lisa F" sort="Licitra, Lisa F" uniqKey="Licitra L" first="Lisa F" last="Licitra">Lisa F. Licitra</name><affiliation wicri:level="3"><nlm:affiliation>Foundation for Cancer Research and Treatment, National Tumor Institute, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Foundation for Cancer Research and Treatment, National Tumor Institute, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Sherman, Steven I" sort="Sherman, Steven I" uniqKey="Sherman S" first="Steven I" last="Sherman">Steven I. Sherman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Ball, Douglas W" sort="Ball, Douglas W" uniqKey="Ball D" first="Douglas W" last="Ball">Douglas W. Ball</name><affiliation wicri:level="2"><nlm:affiliation>The Johns Hopkins University School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>The Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25913680</idno><idno type="pmid">25913680</idno><idno type="doi">10.1002/cncr.29395</idno><idno type="wicri:Area/PubMed/Corpus">002A75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A75</idno><idno type="wicri:Area/PubMed/Curation">002A05</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A05</idno><idno type="wicri:Area/PubMed/Checkpoint">002A05</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A05</idno><idno type="wicri:Area/Ncbi/Merge">002503</idno><idno type="wicri:Area/Ncbi/Curation">002503</idno><idno type="wicri:Area/Ncbi/Checkpoint">002503</idno><idno type="wicri:Area/Main/Merge">003235</idno><idno type="wicri:Area/Main/Curation">003234</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.</title><author><name sortKey="Cabanillas, Maria E" sort="Cabanillas, Maria E" uniqKey="Cabanillas M" first="Maria E" last="Cabanillas">Maria E. Cabanillas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Schlumberger, Martin" sort="Schlumberger, Martin" uniqKey="Schlumberger M" first="Martin" last="Schlumberger">Martin Schlumberger</name><affiliation wicri:level="4"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute and Université Paris-Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute and Université Paris-Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice Poland, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice Poland, Wybrzeze Armii Krajowej 15, 44-101 Gliwice</wicri:regionArea><wicri:noRegion>44-101 Gliwice</wicri:noRegion></affiliation></author><author><name sortKey="Martins, Renato G" sort="Martins, Renato G" uniqKey="Martins R" first="Renato G" last="Martins">Renato G. Martins</name><affiliation wicri:level="2"><nlm:affiliation>Department of Thoracic/Head and Neck Oncology, School of Medicine, University of Washington, Seattle, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>Department of Thoracic/Head and Neck Oncology, School of Medicine, University of Washington, Seattle</wicri:cityArea></affiliation></author><author><name sortKey="Pacini, Furio" sort="Pacini, Furio" uniqKey="Pacini F" first="Furio" last="Pacini">Furio Pacini</name><affiliation wicri:level="1"><nlm:affiliation>Section of Endocrinology, University of Siena, Siena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Section of Endocrinology, University of Siena, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name><affiliation wicri:level="4"><nlm:affiliation>Faculty of Medicine, Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, University of Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Faculty of Medicine, Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, University of Sydney, New South Wales</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Mccaffrey, Judith C" sort="Mccaffrey, Judith C" uniqKey="Mccaffrey J" first="Judith C" last="Mccaffrey">Judith C. Mccaffrey</name><affiliation wicri:level="2"><nlm:affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>H. Lee Moffitt Cancer Center and Research Institute, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Shah, Manisha H" sort="Shah, Manisha H" uniqKey="Shah M" first="Manisha H" last="Shah">Manisha H. Shah</name><affiliation wicri:level="2"><nlm:affiliation>Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Ohio State University Comprehensive Cancer Center, Columbus</wicri:cityArea></affiliation></author><author><name sortKey="Bodenner, Donald L" sort="Bodenner, Donald L" uniqKey="Bodenner D" first="Donald L" last="Bodenner">Donald L. Bodenner</name><affiliation wicri:level="2"><nlm:affiliation>Department of Geriatrics, University of Arkansas for Medical sciences, Little Rock, Arkansas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Arkansas</region></placeName><wicri:cityArea>Department of Geriatrics, University of Arkansas for Medical sciences, Little Rock</wicri:cityArea></affiliation></author><author><name sortKey="Topliss, Duncan" sort="Topliss, Duncan" uniqKey="Topliss D" first="Duncan" last="Topliss">Duncan Topliss</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Andresen, Corina" sort="Andresen, Corina" uniqKey="Andresen C" first="Corina" last="Andresen">Corina Andresen</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="O Brien, James P" sort="O Brien, James P" uniqKey="O Brien J" first="James P" last="O'Brien">James P. O'Brien</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Ren, Min" sort="Ren, Min" uniqKey="Ren M" first="Min" last="Ren">Min Ren</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Funahashi, Yasuhiro" sort="Funahashi, Yasuhiro" uniqKey="Funahashi Y" first="Yasuhiro" last="Funahashi">Yasuhiro Funahashi</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Andover, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Eisai Inc, Andover</wicri:cityArea></affiliation></author><author><name sortKey="Allison, Roger" sort="Allison, Roger" uniqKey="Allison R" first="Roger" last="Allison">Roger Allison</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author><author><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name><affiliation wicri:level="4"><nlm:affiliation>Department of Endocrinology, University of Pisa, Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Endocrinology, University of Pisa, Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region><settlement type="city">Pise</settlement></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Newbold, Kate" sort="Newbold, Kate" uniqKey="Newbold K" first="Kate" last="Newbold">Kate Newbold</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Royal Marsden Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Oncology, Royal Marsden Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Licitra, Lisa F" sort="Licitra, Lisa F" uniqKey="Licitra L" first="Lisa F" last="Licitra">Lisa F. Licitra</name><affiliation wicri:level="3"><nlm:affiliation>Foundation for Cancer Research and Treatment, National Tumor Institute, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Foundation for Cancer Research and Treatment, National Tumor Institute, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Sherman, Steven I" sort="Sherman, Steven I" uniqKey="Sherman S" first="Steven I" last="Sherman">Steven I. Sherman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Ball, Douglas W" sort="Ball, Douglas W" uniqKey="Ball D" first="Douglas W" last="Ball">Douglas W. Ball</name><affiliation wicri:level="2"><nlm:affiliation>The Johns Hopkins University School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>The Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea></affiliation></author></analytic><series><title level="j">Cancer</title><idno type="eISSN">1097-0142</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Agents (therapeutic use)</term><term>Biomarkers, Tumor (analysis)</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Iodine Radioisotopes (adverse effects)</term><term>Iodine Radioisotopes (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Phenylurea Compounds (adverse effects)</term><term>Phenylurea Compounds (therapeutic use)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Quinolines (adverse effects)</term><term>Quinolines (therapeutic use)</term><term>Thyroid Neoplasms (drug therapy)</term><term>Thyroid Neoplasms (mortality)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Marqueurs biologiques tumoraux (analyse)</term><term>Mâle</term><term>Phénylurées (effets indésirables)</term><term>Phénylurées (usage thérapeutique)</term><term>Quinoléines (effets indésirables)</term><term>Quinoléines (usage thérapeutique)</term><term>Radio-isotopes de l'iode (effets indésirables)</term><term>Radio-isotopes de l'iode (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Tumeurs de la thyroïde (mortalité)</term><term>Tumeurs de la thyroïde (traitement médicamenteux)</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Iodine Radioisotopes</term><term>Phenylurea Compounds</term><term>Protein Kinase Inhibitors</term><term>Quinolines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers, Tumor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Iodine Radioisotopes</term><term>Phenylurea Compounds</term><term>Protein Kinase Inhibitors</term><term>Quinolines</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Phénylurées</term><term>Quinoléines</term><term>Radio-isotopes de l'iode</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs de la thyroïde</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs de la thyroïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Inhibiteurs de protéines kinases</term><term>Phénylurées</term><term>Quinoléines</term><term>Radio-isotopes de l'iode</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 through 3 (VEGFR1-VEGFR3), fibroblast growth factor receptors 1 through 4 (FGFR1-FGFR4), platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks implicated in tumor angiogenesis. Positive phase 1 results in solid tumors prompted a phase 2 trial in patients with advanced, radioiodine-refractory, differentiated thyroid cancer (RR-DTC).</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003234 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003234 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:25913680
|texte= A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:25913680" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |